Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 00:30:28 Source:opinionsViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:FDIC chairman Martin Gruenberg to step down, White House says
Next:Adams, Reyna, Turner, Ream are US concerns ahead of Copa America
You may also like
- Young Boys seals 6th Swiss soccer league title in 7 years after rallying from firing coach Wicky
- President Lula has set Brazil on a new diplomatic course
- I visited a £400 wellness retreat in Wales to try the ancient Japanese art of forest bathing
- Embracing the spring season: Hulun Lake in north China
- Messi in and Dybala out in Argentina squad for pre
- Thailand to waive visa requirements for Chinese nationals
- Who is the real
- Civil War viewers are left stunned by Jesse Plemons 'dead
- Burglar hurled stolen mobile phones at police from the top of 60ft high roof during nine